Team Identifies 137 Unique T Cell Epitopes Associated with Active TB

A recent study by La Jolla Institute for Immunology scientists, published in Nature Communications, has provided crucial insights into how human T cells combat Mycobacterium tuberculosis, the bacterium that causes TB. 

"This research gives us a better understanding of T cell responses to different stages in tuberculosis infection and helps us figure out is there are additional diagnostic targets, vaccine targets, or drug candidates to help people with the disease," says  Cecilia Lindestam Arlehamn, who led the new research. 

For the study, the researchers conducted a proteome-wide screen with samples from 21 patients who were mid-treatment for active TB. These samples came from study participants in Peru, Sri Lanka, and Moldova. By looking at T cells in patients from three different continents, the researchers hoped to capture a wide diversity of genetics—and environmental factors—that can affect immune system activity.

Analysis revealed 137 unique T cell epitopes, with 16% of these epitopes being targeted by T cells in two or more patients. This diverse range of epitopes is a significant finding that could inform the development of future TB vaccines and drug therapies.

Additionally, the research has the potential to contribute to the early detection of TB cases before they become deadly. By comparing samples from active TB patients with those from healthy individuals, the study identified key differences in T cell reactivity, offering a potential avenue for developing diagnostics to distinguish between active and latent TB.